Cell and gene therapy Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
18:20
Jan 08
Jan 08
Cell and gene therapies becoming mainstream
Gene therapy technology has advanced through AAV vectors, lipid nanoparticles, and synthetic capsids; FDA has moved toward a reproducible pathway for rare diseases, and cell/gene therapy approvals are approaching 10 per year, making them more mainstream despite regulatory hurdles.
HIGH
13:11
Jan 08
Jan 08
Gene therapy advances; approvals becoming mainstream
Gene and cell therapy technology has advanced materially beyond early AAV vectors through lipid nanoparticles, synthetic capsids, and base editing, and while regulation remains the key roadblock, FDA pathways and a rising approval run rate are making these therapies more mainstream.
HIGH
About Cell and gene therapy Investor Commentary
Across the available history and selected sources, Buzzberg tracks Cell and gene therapy across 1 sources: 2 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Scott Gottlieb.